Stimulating Neuroplasticity for Therapeutic Benefits Inspired by Psychedelic Research [High on Healthy]
Sunday, July 20, 2025 1 min read
Key Takeaway: Dr. Joseph Tucker, CEO of Enveric Biosciences, discusses the company's innovative approach to developing non-hallucinogenic neuroplastogens. These compounds are inspired by psychedelic research and aim to stimulate neuroplasticity, potentially offering significant therapeutic benefits. The conversation highlights the intersection of neuroscience and psychedelic studies in modern medicine.
Price reaction · baseline $15.84 (2025-07-18 close) · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+3.8%
Market Sentiment Analysis
POSITIVE FACTORS
Development of non-hallucinogenic neuroplastogens.
Inspired by promising psychedelic research.
Focus on stimulating neuroplasticity for therapeutic benefits.
Full Press Release Details
Richard Zwicky spoke with Dr. Joseph Tucker, CEO of Enveric Biosciences about their development of non-hallucinogenic neuroplastogens, inspired by psychedelic research, to stimulate neuroplasticity for therapeutic benefits.
Listen to Podcast >>
Frequently Asked Questions
What are neuroplastogens?
Neuroplastogens are compounds developed to stimulate neuroplasticity without causing hallucinations.
Who is Dr. Joseph Tucker?
Dr. Joseph Tucker is the CEO of Enveric Biosciences, focusing on neuroplasticity research.
How are neuroplastogens inspired by psychedelics?
They are inspired by research on psychedelics that shows potential for enhancing neuroplasticity.
What therapeutic benefits do neuroplastogens offer?
They aim to provide significant therapeutic benefits by promoting neuroplasticity.